-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ubidecarenone in Brain Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ubidecarenone in Brain Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ubidecarenone in Brain Cancer Drug Details: Ubidecarenone is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-14927 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFP-14927 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFP-14927 in Pancreatic Cancer Drug Details: DFP-14927 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-14927 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFP-14927 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFP-14927 in Solid Tumor Drug Details: DFP-14927 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DFP-14927 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFP-14927 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFP-14927 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: DFP-14927 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-14927 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFP-14927 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFP-14927 in Gastroesophageal (GE) Junction Carcinomas Drug Details: DFP-14927...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-14927 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFP-14927 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFP-14927 in Refractory Acute Myeloid Leukemia Drug Details: DFP-14927...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-14927 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFP-14927 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFP-14927 in Relapsed Acute Myeloid Leukemia Drug Details: DFP-14927...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tuparstobart in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tuparstobart in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tuparstobart in Metastatic Melanoma Drug Details: Tuparstobart (INCAGN-2385) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maralixibat Chloride in Primary Sclerosing Cholangitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maralixibat Chloride in Primary Sclerosing Cholangitis Drug Details: Maralixibat...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...